63rd ASH Annual Meeting and Exposition: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

Oral and Poster Abstracts
Oral

Biological, Genomics, Bispecific Antibody Therapy, Clinical Research, Plasma Cell Disorders, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies, Monoclonal Antibody Therapy

Hall A1 (Georgia World Congress Center)

Moderators:

Wendy Cozen, DO, MPH, Susan and Henry Samueli College of Health Sciences, University of California at Irvine, University of California at Irvine and Shaji K Kumar, MD, Mayo Clinic

Disclosures:

Kumar: Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Research Funding; Novartis: Research Funding; Tenebio: Research Funding; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beigene: Consultancy; Oncopeptides: Consultancy; Antengene: Consultancy, Honoraria; Carsgen: Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Roche-Genentech: Consultancy, Research Funding; Bluebird Bio: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding.

4:30 PM

817

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD¹, Hang Quach, FRACP, FRCPA², Rachid Baz, MD³^*, Annette J. Vangsted, MD⁴^*, Shir-Jing Ho, FRACP, FRCPA, MBBS⁵^*, Simon J Harrison, MD⁶, Torben Plesner, MD⁷, Philippe Moreau, MD, PhD⁸^*, Simon D. Gibbs⁹^*, Eva Medvedova, MD¹⁰^*, Vasudha Sehgal, PhD¹¹^*, Kingston Kang, PhD¹²^*, Jeremy A. Ross, PhD¹¹^*, L. Leanne Lash-Fleming, PhD¹²^*, Yan Luo, MD PhD¹²^* and Nizar J. Bahlis, MD¹³

¹Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
²St. Vincent’s Hospital, Melbourne, VIC, Australia
³Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Department of Hematology, Rigshospitalet, Copenhagen, Denmark
⁵St George Hospital, Kogarah, AUS
⁶Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
⁷Department of Hematology, Vejle Hospital, Vejle, Denmark
⁸University Hospital Hôtel-Dieu, Nantes, Nantes, France
⁹The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia
¹⁰Oregon Health & Science University, Portland, OR
¹¹AbbVie Inc., North Chicago, IL
¹²AbbVie, Inc., North Chicago, IL
¹³Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

4:45 PM

818

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Xiang Zhou¹^*, Andrej Besse²^*, Jessica Peter, MD³^*, Max Mendez Lopez, MD⁴^*, Larissa Haertle⁵^*, Umair Munawar, PhD⁶^*, Seungbin Han³^*, Elmer Maurits⁷^*, Herman S. Overkleeft⁸^*, Hermann Einsele⁹, Christoph Driessen, MD¹⁰, Martin Kortuem¹¹^*, Lenka Besse¹²^* and Leo Rasche, MD¹³^*

¹Department of Internal Medicine II, Division of Oncology and Hematology, University Hospital Wuerzburg, WüRzburg, Germany
²Kantonsspital St. Gallen, St.Gallen, CHE
³University Hospital Würzburg, Würzburg, Germany
⁴Cantonal Hoapital St Gallen, St Gallen, Switzerland
⁵Department of Internal Medicine II, University Hospital WüRzburg, W, WüRzburg, DEU
⁶Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
⁷Leiden Institute of Chemistry and Netherlands Proteomics Centre, Leiden, Netherlands
⁸Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
⁹Department of Internal Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
¹⁰Department of Oncology and Hematology, Laboratory of Experimental Oncology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
¹¹Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
¹²Department of Oncology and Hematology, Laboratory of Experimental Oncology, Kantonal Hospital St Gallen, St Gallen, Switzerland
¹³University Hospital Würzburg, Würzburg, Bayern, Germany

5:00 PM

819

Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience

Sarah Goldman-Mazur, MD¹^*, Alissa Visram, MD^2,3^*, S Vincent Rajkumar, MD⁴^*, Prashant Kapoor, MD³, Angela Dispenzieri, MD³, Martha Q. Lacy, MD¹, Morie A. Gertz, M.D.³, Francis K. Buadi, MB, CHB⁵^*, Suzanne R. Hayman, M.D.³, David Dingli, M.D., Ph.D.³, Taxiarchis Kourelis, M.D.³, Wilson I Gonsalves, MD³, Rahma M Warsame, MD³, Eli Muchtar, MD³^*, Nelson Leung, MD¹, Robert A. Kyle, MD³ and Shaji K Kumar, MD⁶

¹Division of Hematology, Mayo Clinic Rochester, Rochester, MN
²Division of Hematology, Ottawa Hospital Research Institute, Ottawa, ON, Canada
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Mayo Clinic, Rochester
⁵Mayo Clinic Rochester, Division of Hematology, Rochester, MN
⁶Mayo Clinic, Rochester, MN

5:15 PM

820

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, FRCPath, MRCP¹^*, Mark T Drayson, MD²^*, Nicola Wright, MChem³^*, Gordon Cook, MD^4,5^*, Faith E. Davies⁶^*, Gareth J Morgan, MD, PhD⁶^*, Ruth M. de Tute, PhD, FRCPath⁷^*, Roger G Owen, MD⁸^*, David Cairns, PhD⁵^*, Anna Hockaday⁹^*, Tom Menzies⁵^*, Martin F. Kaiser, MD, FRCP, FRCPath¹⁰, Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, FRCPath¹¹, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM¹² and Guy Pratt, MD FRCP FRCPath^13,14

¹University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, United Kingdom
²Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
³The Binding Site Ltd, Birmingham, United Kingdom
⁴Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
⁵Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
⁶NYU Langone Health, Myeloma Research Program, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY
⁷Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom
⁸St. James's University Hospital, Leeds, United Kingdom
⁹Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds, United Kingdom
¹⁰The Institute of Cancer Research, London, United Kingdom
¹¹Institute of Cancer Research, Sutton, United Kingdom
¹²Department of Haematology, NCCC Freeman Road Hospital, Newcastle Upon Tyne, United Kingdom
¹³Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
¹⁴University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

5:30 PM

821

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, MD¹, Oliver Van Oekelen, MD, MSc², Darren Pan, MD, BS³^*, Sarita Agte, MD⁴^*, Adolfo Aleman, MPA²^*, David T. Melnekoff, MS⁵^*, Guido Lancman, MD³, Santiago Thibaud, MD⁶, Larysa Sanchez, MD⁴^*, Shambavi Richard³^*, Joshua Richter, MD³, Hearn Jay Cho, MD, PhD³, Ajai Chari, MD⁷, Sundar Jagannath⁸ and Samir Parekh, MD³

¹Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
³Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁵Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
⁶Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁸Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY

5:45 PM

822

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

Oliver Van Oekelen, MD, MSc^1,2,3, Sarita Agte, MD^2,4^*, Adolfo Aleman, MPA^2,3^*, Bhaskar Upadhyaya, PhD^2,4^*, Charles R. Gleason, BS⁵^*, Komal Srivastava, MS⁵^*, Katherine F. Beach, BA⁵^*, Kevin Tuballes, MD^6,7^*, Katerina Kappes, BSc^2,4^*, Tarek H. Mouhieddine, MD⁸, Bo Wang, MD⁴^*, Seunghee Kim-Schulze, PhD^2,6^*, Ajai Chari, MD^4,9^*, Sacha Gnjatic, PhD^2,6,7,10^*, Nina Bhardwaj, MD, PhD^2,4,7,11^*, Brian D. Brown, PhD^1,2,7^*, Miriam Merad, MD^2,4,6,7,10^*, Carlos Cordon-Cardo, MD, PhD^1,10,12^*, Florian Krammer, PhD^5,13^*, Sundar Jagannath, MD^2,4^*, Viviana Simon, MD, PhD^5,14,15^*, Ania Wajnberg, MD^16,17^* and Samir Parekh, MD^2,4,7,10

¹Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
²Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
³Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
⁴Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁵Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
⁶Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁸Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
⁹Mount Sinai, New York, NY
¹⁰Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
¹¹Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY
¹²Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
¹³Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁴Department of Medicine, Division of Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁵Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁶Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
¹⁷Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O5.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor